Aldeyra Therapeutics News

Express News | Aldeyra Therapeutics Inc: Clinical Trial Results and Potential New Drug Application Resubmission Expected in Second Half of 2024

ReutersJun 13 07:00 ET

Express News | Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

ReutersJun 13 07:00 ET

Aldeyra Therapeutics to Host Investor Roundtable QA

PDF Version Event Scheduled for Thursday, June 20 at 8:00 a.m. ET LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 12, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company dev

Aldeyra TherapeuticsJun 12 00:00 ET

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

PDF Version LEXINGTON, Mass.--(BUSINESS WIRE)--May 29, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the tre

Aldeyra TherapeuticsMay 29 00:00 ET

Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)

TipRanksMay 24 01:51 ET

Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?

Yahoo FinanceMay 14 09:40 ET

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study

Aldeyra Therapeutics (ALDX) said Wednesday the first patient has been enrolled in a phase 3 dry eye chamber trial of reproxalap in dry eye disease. Reproxalap is an investigational reactive aldehyde s

MT NewswiresMay 8 15:12 ET

Express News | Aldeyra Therapeutics Enrolls First Patient in Phase 3 Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease, Clinical Results and Potential New Drug Application Submission Expected In 2H Of 2024

BenzingaMay 8 07:14 ET

Express News | Aldeyra Therapeutics Inc - Clinical Results and Potential New Drug Application Submission Expected in Second Half of 2024

ReutersMay 8 07:00 ET

Express News | Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

ReutersMay 8 07:00 ET

Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer

Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer

Dow JonesMay 6 07:57 ET

Oppenheimer Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)

TipRanksMay 6 07:47 ET

Express News | HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

BenzingaMay 6 06:38 ET

Analysts Offer Insights on Healthcare Companies: Owens & Minor (OMI), Vertex Pharmaceuticals (VRTX) and Aldeyra Therapeutics (ALDX)

TipRanksMay 6 06:20 ET

Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)

TipRanksApr 30 03:31 ET

Aldeyra Therapeutics Unveils R&D Progress and Goals

TipRanksApr 25 07:13 ET

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.

BusinesswireApr 25 07:00 ET

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

PDF Version LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 18, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the tr

Aldeyra TherapeuticsApr 18 00:00 ET

Aldeyra Therapeutics(ALDX.US) 10% Shareholder Buys US$833.87K in Common Stock

$Aldeyra Therapeutics(ALDX.US)$ 10% Shareholder PERCEPTIVE ADVISORS LLC purchased 177.99K shares of common stock on Apr 4, 5, 2024 at an average price of $4.68 for a total value of $833.87K. This tran

moomoo NewsApr 8 18:12 ET

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

Aldeyra Therapeutics’ALDX clinical-stage immunology pipeline comprises two candidates, reproxalap and ADX-629, which are undergoing late-stage and mid-stage development, respectively.

Yahoo FinanceApr 6 06:37 ET